Stelara

Moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy. Monotherapy or in combination w/ MTX in adults w/ active psoriatic arthritis (PsA). Moderate to severe active Crohn's disease in adults who have failed or were intolerant to immunomodulators, corticosteroids or ≥1 anti-TNF treatment, or were corticosteroid-dependent. Moderately to severely active ulcerative colitis in adults.

Plaque psoriasis & PsA 45 mg SC administered at wk 0 & 4, then every 12 wk thereafter. Alternatively, 90 mg may be used in patient >100 kg. Crohn's disease & ulcerative colitis Patient >85 kg 520 mg as single IV dose, followed by 90 mg SC 8 wk later, then every 8 wk thereafter, >55 to ≤85 kg 390 mg as single IV dose, followed by 90 mg SC 8 wk later, then every 8 wk thereafter, ≤55 kg 260 mg as single IV dose, followed by 90 mg SC 8 wk later, then every 8 wk thereafter.

Hypersensitivity.

Discontinue use if an anaphylactic or other serious hypersensitivity reaction occurs. Not to be given to patients w/ clinically important, active infection or active TB. May potentially increase risk of infections & malignancy, & reactivate latent infections. Patients w/ chronic infection or history of recurrent infection; history of malignancy or those who develop malignancy. Contains dry natural rubber which may cause allergic reactions in latex-sensitive individuals. Evaluate patients for TB infection prior to initiating treatment. Closely monitor for signs & symptoms of active TB during & after treatment; if patient develops serious infection & do not administer treatment until infection resolves. Monitor for appearance of non-melanoma skin cancer in patient particularly those >60 yr, w/ medical history of prolonged immunosuppressant therapy or w/ history of PUVA treatment. Not to be given concurrently w/ live viral or bacterial vaccines. Combination w/ immunosuppressive agents or phototherapy, or when transitioning from other biologic agents; allergy immunotherapy particularly for anaphylaxis. No studies conducted in patients w/ renal or hepatic impairment; childn <12 yr; ped patients w/ Crohn's disease or ulcerative colitis. Pregnancy & lactation. Elderly ≥65 yr.

URTI, nasopharyngitis, sinusitis; dizziness, headache; oropharyngeal pain; diarrhea, nausea, vomiting; pruritus; back pain, myalgia, arthralgia; fatigue, inj site erythema & pain.

Not to be concurrently given w/ live vaccines.

Immunosuppressants

L04AC05 - ustekinumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

Rx